Currently, SelenoExcell® research efforts are underway with several prominent research groups. SelenoExcell® has been selected as the intervention agent in a series of health and cancer prevention studies. The series of studies are funded by the National Cancer Institute (NCI), National Institute of Health (NIH), United States Department of Agriculture (USDA), Department of Defense (DOD) and numerous private-funding organizations.

At this time we are unable to discuss the details of the research projects, because they are double-blinded, randomized trials. Discussing the details of the clinical trials could potentially jeopardize the integrity and results of the trials.

Cypress has also signed a Clinical Trial Agreement (CTA) with the National Cancer Institute's Division on Cancer Prevention (DCP) (link to press release). The agreement is to promote the use of SelenoExcell® High Selenium Yeast in clinical trials that my lead to a New Drug Application (NDA) and a Biological License Application (BLA). The NDA and BLA are vehicles by which natural products like SelenoExcell® are made widely available to cancer patients and the general public as cancer prevention and control therapies.

• National Cancer Institute (NCI) United States and Canada
• National Institute of Health (NIH) United States
• Department of Agriculture (USDA)
• Department of Defense (DOD)
• International Cancer Alliances

• Randomized Controlled Clinical Trial
• Double Blinded
• Placebo Controlled
• Primary and Secondary End Points
• Long Term Studies
• Peer Reviewed
• Journal Publication

Prior to his death in March 2000, Larry C. Clark, M.P.H., Ph.D., University of Arizona, Arizona Cancer Center had announced that his original Nutritional Prevention of Cancer Trial had been extended for 3 years and supported by renewed funding of $2,500,000 from the National Cancer Institute.

Following the unblinding of the original study group, the remaining participants have been placed on selenium supplementation. The selected intervention agent and source of organically bound selenium is SelenoExcell®; High Selenium Yeast.

The objectives of the trial are:

1. Establish long-term safety of selenium supplementation
2. Continue trend analysis of previous data points
3. Identify possible mechanisms for cancer prevention response through biopsy testing

Nutritional Prevention of Cancer Trial was published in The Journal of the American Medical Association, Vol. 276 No. 24: 1957 - 1963, 1996 and the British Journal of Urology, Vol. 81: 730 - 734, 1998.

	All Cause Mortality	17%
	Total Cancer Mortality	50%
	Total Cancer Incidence	37%
	Lung Cancer Incidence	46%
	Colon Cancer Incidence	58%
	Prostate Cancer Incidence	63%

<< back to Research